[
  {
    "ts": "2026-01-09T14:50:00+00:00",
    "headline": "Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026",
    "summary": "It could be another tough year for the once-soaring drugmaker.",
    "url": "https://www.fool.com/investing/2026/01/09/prediction-2-healthcare-stocks-that-will-be-worth/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "fb1dc6f6-fe3c-30c3-b797-761ee9fc296d",
      "content": {
        "id": "fb1dc6f6-fe3c-30c3-b797-761ee9fc296d",
        "contentType": "STORY",
        "title": "Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026",
        "description": "",
        "summary": "It could be another tough year for the once-soaring drugmaker.",
        "pubDate": "2026-01-09T14:50:00Z",
        "displayTime": "2026-01-09T14:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/e3f1540620bfc4477074aebbb5a01ad2",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Physician and patient discussing the patient's healthcare plan.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xoU0cGmPqAAerl5W7BPCxw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/e3f1540620bfc4477074aebbb5a01ad2.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MrOCsdynpkM3tB7i_.kPhA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/e3f1540620bfc4477074aebbb5a01ad2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/09/prediction-2-healthcare-stocks-that-will-be-worth/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/prediction-2-healthcare-stocks-worth-145000390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "MDT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T15:13:38+00:00",
    "headline": "Assessing Vertex Pharmaceuticals (VRTX) Valuation After Wolfe Research Upgrade And Growing Pipeline Optimism",
    "summary": "Vertex Pharmaceuticals (VRTX) is back in focus after Wolfe Research upgraded the stock to Outperform, citing increased confidence in its investigational IgA nephropathy therapy and plans to use a priority review voucher. See our latest analysis for Vertex Pharmaceuticals. The Wolfe upgrade comes after a solid run, with a 90 day share price return of 15.18% and a 1 year total shareholder return of 13.97%. This suggests momentum has been building around Vertex’s pipeline story beyond cystic...",
    "url": "https://finance.yahoo.com/news/assessing-vertex-pharmaceuticals-vrtx-valuation-151338319.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "f4b0bd56-9ef4-3ef8-a589-c657643483b0",
      "content": {
        "id": "f4b0bd56-9ef4-3ef8-a589-c657643483b0",
        "contentType": "STORY",
        "title": "Assessing Vertex Pharmaceuticals (VRTX) Valuation After Wolfe Research Upgrade And Growing Pipeline Optimism",
        "description": "",
        "summary": "Vertex Pharmaceuticals (VRTX) is back in focus after Wolfe Research upgraded the stock to Outperform, citing increased confidence in its investigational IgA nephropathy therapy and plans to use a priority review voucher. See our latest analysis for Vertex Pharmaceuticals. The Wolfe upgrade comes after a solid run, with a 90 day share price return of 15.18% and a 1 year total shareholder return of 13.97%. This suggests momentum has been building around Vertex’s pipeline story beyond cystic...",
        "pubDate": "2026-01-09T15:13:38Z",
        "displayTime": "2026-01-09T15:13:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-vertex-pharmaceuticals-vrtx-valuation-151338319.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-vertex-pharmaceuticals-vrtx-valuation-151338319.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]